Pancreatic Juice Biomarker for Pancreatic Cancer

描述（申请人提供）：胰腺癌是一种高致死性疾病，诊断和治疗非常困难，有效治疗胰腺癌的关键在于早期诊断。由于目前用于诊断极早期胰腺癌的方法是无效的，因此迫切需要新的生物标志物。这些生物标志物将特别有用的患者谁是在发展胰腺癌的风险增加，谁有一个异常的胰腺，因为慢性胰腺炎或囊性病变。由于肿瘤进展的不确定性，此类病变可能难以管理。胰液是一种近端体液，代表了一种用于识别胰腺癌生物标志物的合适标本。癌细胞优先流入导管腔，使果汁成为癌症相关标志物的丰富来源。在过去的几年中，已经通过蛋白质组学和其他技术鉴定了大量的胰腺癌生物标志物候选者。这些候选生物标志物的验证是缩小实验室研究与临床应用之间的差距的重要一步，也是胰腺癌诊断生物标志物开发的主要瓶颈。在拟议的研究中，我们计划表征一组选定的胰腺癌生物标志物候选物在胰腺癌检测的胰液中的表现。我们的患者队列将包括那些患有癌症和早期癌前病变的患者与患有囊性病变和胰腺炎的疾病对照组。生物标志物开发的补充方法将结合联合收割机最先进的免疫测定和靶向蛋白质组学测定。这些测定将用于评价临床胰液标本中的候选蛋白。本研究开发的生物标志物可用于辅助评估接受内镜手术的高风险患者。这些生物标志物也有可能进一步发展为基于血液的检测，用于胰腺癌的早期检测。 公共卫生相关性：我们计划研究胰腺癌早期检测的生物标志物。如果我们在这一目标上取得成功，我们可能会在这种致命癌症的检测和管理方面产生重大影响。

DESCRIPTION (provided by applicant): Pancreatic cancer is a highly lethal disease that is very difficult to diagnose and treat. The effective treatment of pancreatic cancer is critically relying on the diagnosis of the disease at an early stage. Because the current methods for diagnosing very early pancreatic cancer are ineffective, there is an urgent need for new biomarkers. These biomarkers would be particularly useful in patients who are at increased risk of developing pancreatic cancer and who have an abnormal pancreas because of chronic pancreatitis or cystic lesions. Such lesions can be difficult to manage because of the uncertainty regarding neoplastic progression. Pancreatic juice is a proximal body fluid and represents an opportune specimen for identifying biomarkers of pancreatic cancer. Cancer cells are preferentially shed into the ductal lumen, making juice a rich source of cancer associated markers. In the past few years, a large number of pancreatic cancer biomarker candidates have been identified by proteomics and other techniques. Validation of these biomarker candidates is an important step to close the gap between bench research and clinical application, and has been the major bottleneck for biomarker development for pancreatic cancer diagnosis. In the proposed study, we plan to characterize a selected group of pancreatic cancer biomarker candidates for their performance in pancreatic juice for pancreatic cancer detection. Our patient cohort will include those with cancer and the early stages of pre-cancer versus diseased controls with cystic lesions and pancreatitis. A complementary approach of biomarker development will combine state-of-the-art immunoassays and targeted proteomic assays. These assays will be applied to evaluate the protein candidates in clinical pancreatic juice specimens. Biomarkers developed from this study could be used to aide in assessment of high-risk patients undergoing endoscopic procedures. It is also possible that these biomarkers could be further developed into blood based test for early detection of pancreatic cancer. PUBLIC HEALTH RELEVANCE: We plan to investigate biomarkers for early detection of pancreatic cancer. If we are successful in this goal, it is likely that we could make a significant impact in the detection and management of this deadly cancer.